Key result
Prospective EV-A71 vaccination is predicted to drastically reduce EV-A71 incidence without a substantial competitive release of CV-A16, with cross-protection estimated at 9.95 weeks (95% CI 3.31-23.40).
Why the study?
Does EV-A71 vaccination reduce overall HFMD burden without causing substantial serotype replacement by CV-A16?
Population
Weekly reports of Hand, Foot, and Mouth Disease incidence from 31 provinces in Mainland China from 1 January…
Design
Other
Follow-up
1 January 2009 to 31 December 2013 (data period)
Authors
Loading...
EV-A71 vaccination may reduce HFMD incidence without CV-A16 replacement; modeling leaves open prospective validation.
Does EV-A71 vaccination reduce overall HFMD burden without causing substantial serotype replacement by CV-A16?
Effect estimate: 9.95 weeks (95% CI 3.31-23.40)
Mathematical modeling suggests that a mass EV-A71 vaccination program would drastically reduce EV-A71 incidence without substantial competitive release of CV-A16.
Takahashi et al. (2016) studied Hand, foot, and mouth disease (HFMD). Prospective EV-A71 vaccination vs. Pre-vaccination period was evaluated on Duration of cross-protection following infection with EV-A71 or CV-A16 (9.95 weeks, 95% CI 3.31-23.40). Prospective EV-A71 vaccination is predicted to drastically reduce EV-A71 incidence without a substantial competitive release of CV-A16, with cross-protection estimated at 9.95 weeks (95% CI 3.31-23.40).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: